Abvc Biopharma (ABVC) Enterprise Value (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Enterprise Value came in at $1.9 million in Q1 2026, up 3.41% YoY from $1.8 million in Q1 2025, and up 28.73% on a QoQ basis from $1.4 million in Q4 2025.
Abvc Biopharma (ABVC) Enterprise Value (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 15 years of Enterprise Value data on file, last reported at $1.9 million in Q1 2026.
- Quarterly Enterprise Value rose 3.41% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (up 3.41% YoY) and the FY2025 annual result came in at $1.4 million, up 205.4% from the prior year.
- Enterprise Value grew to $1.9 million in Q1 2026, from $1.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of $2.2 million in Q3 2025 to a low of -$2.3 million in Q3 2022.
- A 5-year average of -$309271.5 and a median of -$925210.0 in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value tumbled 210.38% — and 2025, when it jumped 304.53%.
- Tracing ABVC's Enterprise Value over 5 years: stood at -$1.3 million in 2022, then jumped by 66.91% to -$440104.0 in 2023, then plunged by 210.38% to -$1.4 million in 2024, then soared by 205.4% to $1.4 million in 2025, then grew by 28.73% to $1.9 million in 2026.
- The last three Enterprise Value figures came in at $1.9 million (Q1 2026), $1.4 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Abvc Biopharma | 23.34 Mn | 23.34 Mn | - | 1.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.89 Mn |
| Mar 31, 2026 | 1.85 Mn |
| Dec 31, 2025 | 1.44 Mn |
| Sep 30, 2025 | 2.18 Mn |
| Jun 30, 2025 | 2.02 Mn |
| Mar 31, 2025 | 1.79 Mn |
| Dec 31, 2024 | -1.37 Mn |
| Sep 30, 2024 | -1.07 Mn |
| Jun 30, 2024 | -988,926.00 |
| Mar 31, 2024 | -1.53 Mn |
| Dec 31, 2023 | -440,104.00 |
| Sep 30, 2023 | -1.23 Mn |
| Jun 30, 2023 | -707,381.00 |
| Mar 31, 2023 | -1.81 Mn |
| Dec 31, 2022 | -1.33 Mn |
| Sep 30, 2022 | -2.27 Mn |
| Jun 30, 2022 | -925,210.00 |
| Mar 31, 2022 | -875,691.00 |
| Dec 31, 2021 | -6.65 Mn |
| Sep 30, 2021 | -4.83 Mn |